Advertisement

Onabotulinum Toxin Injection and Headaches

  • Andrew BlumenfeldEmail author
  • Stephen D. Silberstein
  • Michael L. Oshinsky
Chapter

Abstract

Onabotulinum toxin A (botulinum toxin type A, Botox®) is a focally acting neurotoxin that inhibits the release of neurotransmitters from presynaptic nerves. Preclinical evidence has shown that onabotulinum toxin A has anti-inflammation and antinociceptive properties. Onabotulinum toxin A is a safe and effective treatment for chronic migraine. Seven botulinum toxin serotypes are produced by Clostridium botulinum (i.e., A, B, C, D, E, F, and G). Botulinum toxins consist of a heavy chain of 100 kDa and a light chain of 50 kDa linked by a single disulfide bond and are synthesized as a relatively inactive single-chain polypeptide.

Keywords

Botulinum Toxin Chronic Migraine Chronic Daily Headache Headache Frequency Cervical Dystonia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Cui M, Khanijou S, Rubino J, Aoki KR. Botulinum toxin A inhibits the inflammatory pain in the rat formalin model. Soc Neurosci. 2000;26:656 (Abstract).Google Scholar
  2. 2.
    Cui M, Li Z, You S, Khanijou S, Aoki K. Subcutaneous BOTOX inhibits formalin-induced local neurotransmitter release and spinal nociceptive processing. 2002. 17 Aug 2002. (GENERIC) Ref Type: Conference Proceeding.Google Scholar
  3. 3.
    Aoki KR. Physiology and pharmacology of therapeutic botulinum neurotoxins. Curr Probl Dermatol. 2002;30:107–16.PubMedCrossRefGoogle Scholar
  4. 4.
    Smuts JA, Baker MK, Smuts M, Stassen JM, Rossouw E, Barnard PW. Prophylactic treatment of chronic tension-type headache using botulinum toxin type A. Eur J Neurol. 1999;6:99–102.CrossRefGoogle Scholar
  5. 5.
    Binder WJ, Brin MF, Blitzer A, Shoenrock LD, Pogoda JM. Botulinum toxin type A (Botox) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg. 2000;123:669–76.PubMedCrossRefGoogle Scholar
  6. 6.
    Freund BJ, Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: a pilot study. Headache. 2000;40:231–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Silberstein SD, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache. 2000;40:445–50.PubMedCrossRefGoogle Scholar
  8. 8.
    Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45:293–307.PubMedCrossRefGoogle Scholar
  9. 9.
    Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache. 2008;48:210–20.PubMedCrossRefGoogle Scholar
  10. 10.
    Dodick D, Aurora S, Turkel C, et al. Botulinum toxin type A for treatment of chronic migraine; the double blind phase of the PREEMPT clinical program. Cephalalgia. 2009;29 Suppl 1:34 (Abstract).Google Scholar
  11. 11.
    Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921–36.PubMedCrossRefGoogle Scholar
  12. 12.
    Diener H-C, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–14.PubMedCrossRefGoogle Scholar
  13. 13.
    Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803.PubMedCrossRefGoogle Scholar
  14. 14.
    Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50:1406–18.PubMedCrossRefGoogle Scholar
  15. 15.
    Rowland LP. Stroke, spasticity, and botulinum toxin. N Engl J Med. 2002;347:382–3.PubMedCrossRefGoogle Scholar
  16. 16.
    Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003;43 Suppl 1:S16–24.PubMedCrossRefGoogle Scholar
  17. 17.
    Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes; a comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001;8 suppl 5:21–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Foran PG, Mohammed N, Lisk GO, et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem. 2003;278:1363–71.PubMedCrossRefGoogle Scholar
  19. 19.
    de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999;96:3200–5.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Meunier FA, Lisk G, Sesardic D, Dolly JO. Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol Cell Neurosci. 2003;22:454–66.PubMedCrossRefGoogle Scholar
  21. 21.
    Naumann M, Yakoleff A, Durif F. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol. 2002;249:57–63.PubMedCrossRefGoogle Scholar
  22. 22.
    Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347:395–400.PubMedCrossRefGoogle Scholar
  23. 23.
    Jankovic J, Schwartz KS. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology. 1993;43:834–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Lew MF, Adornato BT, Duane D, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997;49:701–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53:1439–46.PubMedCrossRefGoogle Scholar
  26. 26.
    Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53:1431–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med. 1991;324:1186–94.PubMedCrossRefGoogle Scholar
  28. 28.
    Jankovic J. Medical therapy and botulinum toxin in dystonia. Adv Neurol. 1998;78:169–83.PubMedGoogle Scholar
  29. 29.
    Kitamura Y, Matsuka Y, Spigelman I, et al. Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience. 2009;159:1422–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Oshinsky ML. Botulinum toxins and migraine: how does it work. Pract Neurol. 2004;(Suppl):10–3.Google Scholar
  31. 31.
    Matak I, Bach-Rojecky L, Filipovi B, Lackovic Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience. 2011;186:201–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Mark MA, Colvin LA, Duggan AW. Spontaneous release of immunoreactive neuropeptide Y from the central terminals of large diameter primary afferents of rats with peripheral nerve injury. Neuroscience. 1998;83:581–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Gardell LR, Vanderah TW, Gardell SE, et al. Enhanced evoked excitatory transmitter release in experimental neuropathy requires descending facilitation. J Neurosci. 2003;23:8370–9.PubMedGoogle Scholar
  34. 34.
    Oshinsky ML, Luo J. Neurochemistry of trigeminal activation in an animal model of migraine. Headache. 2006;46:S39–44.PubMedCrossRefGoogle Scholar
  35. 35.
    Oshinsky M, Gomonchareonsiri S. Dural stimulation in awake rats: a model for recurrent headache. Headache. 2011;47:1026–36.CrossRefGoogle Scholar
  36. 36.
    Ma W, Quirion R. Increased calcitonin gene-related peptide in neuroma and invading macrophages is involved in the upregulation of interleukin-6 and thermal hyperalgesia in a rat model of neuropathy. J Neurochem. 2006;98:180–92.PubMedCrossRefGoogle Scholar
  37. 37.
    Mika J, Rojeswka E, Makuch W, et al. The effect of botulinum neurotoxin A on sciatic nerve injury-induced neuroimmunological changes in rat dorsal root ganglia and spinal cord. Neuroscience. 1998;2011:358–66.Google Scholar
  38. 38.
    Humm AM, Pabst C, Lauterburg T, Burgunder JM. Enkephalin and aFGF are differentially regulated in rat spinal motoneurons after chemodenervation with botulinum toxin. Exp Neurol. 2000;161:361–72.PubMedCrossRefGoogle Scholar
  39. 39.
    Malick A, Burstein R. Peripheral and central sensitization during migraine. Funct Neurol. 2000;15 Suppl 3:28–35.PubMedGoogle Scholar
  40. 40.
    Guyuron B, Tucker T, Davis J. Surgical treatment of migraine headaches. Plast Reconstr Surg. 2002;109:2183–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Ishikawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol. 2000;44:106–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000;38:245–58.PubMedCrossRefGoogle Scholar
  43. 43.
    Morris JL, Jobling P, Gibbins IL. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol. 2001;281:H2124–32.PubMedGoogle Scholar
  44. 44.
    Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental model of trigeminal sensitization. Pain. 2006;122:315–25.PubMedCrossRefGoogle Scholar
  45. 45.
    Schmitt WJ, Slowey E, Fravi N, Weber S, Burgunder JM. Effect of Botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache. 2001;41:658–64.PubMedCrossRefGoogle Scholar
  46. 46.
    Silberstein SD, Gobel H, Jensen R, et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia. 2006;26:790–800.PubMedCrossRefGoogle Scholar
  47. 47.
    Freitag FG. Botulinum toxin type A (BnTxA) in the treatment of chronic migraine. Headache. 2006;46:849 (Abstract).Google Scholar
  48. 48.
    Mathew NT, Kaup AO. The use of botulinum toxin type A in headache treatment. Curr Treat Options Neurol. 2002;4:365–73.PubMedCrossRefGoogle Scholar
  49. 49.
    Silberstein SD, Lipton RB, Solomon S, Mathew NT. Classification of daily and near daily headaches: proposed revisions to the IHS classification. Headache. 1994;34:1–7.CrossRefGoogle Scholar
  50. 50.
    Aurora SK, Nagesh V, Norris LL, Welch KM. Functional imaging of subcortical nociceptive structures in response to treatment of chronic daily headache. Neurology. 2002;58(7):A91 (Abstract).Google Scholar
  51. 51.
    Blumenfeld AM, Binder W, Silbrestein SD, Blizter A. Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache. 2003;43:884–91.PubMedCrossRefGoogle Scholar
  52. 52.
    Aurora SK, Gawel M, Brandes J, Pokta S, VanDenburgh AM. Botulinum toxin type A prophylactic treatment for episodic migraine using a modified follow-the-pain treatment paradigm: a randomized, double-blind, placebo-controlled Phase II study. Headache. 2005;45:766–840.CrossRefGoogle Scholar
  53. 53.
    Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache. 2003;43:171–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Smith T, Stoneman J. Medication overuse headache from antimigraine therapy: clinical features, pathogenesis and management. Drugs. 2004;64:2503–14.PubMedCrossRefGoogle Scholar
  55. 55.
    Freitag FG, McAllister P, Freund B, et al. Botulinum toxin type A for the prophylaxis of chronic daily headache in migraineurs: effect on acute headache pain medication use. J Neurol. 2005;252:62 (Abstract).CrossRefGoogle Scholar
  56. 56.
    Silberstein SD, Olesen J, Bousser MG, et al. The International Classification of Headache Disorders, 2nd edition (ICHD-II)–revision of criteria for 8.2 Medication-overuse headache. Cephalalgia. 2005;25:460–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Saper JR, Brandes J, Wrubel B, Dodick DW, DeGryse R, VanDenburgh AM. Efficacy of prophylactic treatment with Botulinum Toxin Type A in migraineurs with chronic daily headache overusing acute headache pain medications. Headache. 2005;45:825 (Abstract).Google Scholar
  58. 58.
    Silberstein SD, Stark SR, Lucas SM, Christie SN, DeGryse RE, Turkel CC. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2005;80:1126–37.PubMedCrossRefGoogle Scholar
  59. 59.
    Porter JA, Hill JEG, McKenzie B, Porter K, Williams Guynn N. A randomized, double-blind comparison of botulinum toxin Type A (BOTOX) and divalproex sodium (DEPAKOTE) for the prophylactic treatment of episodic migraine: a pilot study. Headache. 2006;46:847 (Abstract).CrossRefGoogle Scholar
  60. 60.
    Blumenfeld A, Schim J. Botulinum toxin type A compared with divalproex sodium for the prophylactic treatment of migraine: a 9 month randomized, double-blind trial. Headache. 2006;46:847 (Abstract).Google Scholar
  61. 61.
    Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011;51(1):21–32.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Andrew Blumenfeld
    • 1
    Email author
  • Stephen D. Silberstein
    • 2
  • Michael L. Oshinsky
    • 2
  1. 1.The Headache Center of Southern CaliforniaSan DiegoUSA
  2. 2.Department of NeurologyJefferson Headache Center, Thomas Jefferson UniversityPhiladelphiaUSA

Personalised recommendations